Indoco Remedies cash flow

Latest FY26

Cash from operations: ₹192cr+102.5% on FY25
Capital spending: ₹148cr−58.6% on FY25
Free cash flow: ₹44.7cr−₹261 cr in FY25
Cash from financing: −₹76.8cr₹241 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	126	114	91.9	70.6
	—	122	66.2	37.7	27.2
	—	−1.4	−0.8	−4.0	−0.6
	—	0.7	2.2	2.9	0.7
	—	−8.6	1.6	0.4	7.3
	—	0.6	−0.2	0.4	1.3
	—	9.3	0.8	8.3	14.4
	—	14.1	−66.3	−27.1	−15.5
	—	−137	50.7	−63.8	−78.8
	—	−10.9	1.8	−4.8	21.0
	—	−0.5	−0.0	−5.5	−1.4
	—	−16.1	−33.8	−40.4	8.2
	—	−14.4	−0.5	−3.7	5.1
	—	105	54.6	30.1	−8.7
	—	29.4	−8.7	28.8	−28.4
	—	47.8	3.5	5.1	7.7
	—	35.1	8.7	−5.1	12.1
	—	0.0	0.0	0.0	−0.1
	—	1.7	−3.2	−1.2	2.1
	—	1.7	−3.9	0.3	3.6
Cash from operating activities
	45.6	−107	−74.4	136	193
	—	305	186	50.4	47.7
	—	198	112	186	240
	—	6.2	17.1	29.5	61.7
	—	192	94.9	157	179
Cash from investing activities
	—	148	356	427	207
	—	46.6	3.8	1.7	1.2
	—	0.0	0.0	6.2	2.4
	—	0.0	7.9	0.0	0.0
	—	1.4	0.8	4.5	0.5
	—	−2.1	4.5	−6.4	−0.1
	—	−102	−339	−434	−208
Cash from financing activities
	—	1.3	1.6	0.8	0.0
	—	147	264	251	95.0
	—	88.7	−58.6	−89.2	22.5
	—	11.0	5.2	0.0	0.0
	—	—	—	3.8	1.8
	—	123	63.9	36.1	27.2
	—	1.9	13.9	20.7	20.7
	—	−0.4	0.0	0.0	0.0
	—	−76.8	241	280	22.8
	—	13.8	−2.8	3.3	−6.5
	—	13.8	−2.8	3.3	−6.5
	—	—	—	14.9	10.9
Reference items
	169	142	99.3	244	286
	8.8%	7.7%	6.0%	13.4%	17.2%
	44.7	44.7	−261	−271	−28.4
	—	−35.7	−3.5	32.4	—
	₹4.84	₹4.84	−₹28.30	−₹29.32	−₹3.08
	44.14×	—	—	—	—
	—	−1.95×	−1.22×	1.62×	1.26×
	—	6.2	17.1	29.5	61.7
	—	123	63.9	36.1	27.2

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INDOCO₹213.75

Indoco Remedies Limited

· Pharma & Health

₹ CrorePeersSAIPARENT PANACEABIO HIKAL WINDLAS HESTERBIO DCAL SYNCOMF SOLARAMcap ₹1,973 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	70.6	91.9	113.8	126.5	—
+ Finance Costs	27.2	37.7	66.2	122.3	—
+ Interest Income	-0.6	-4.0	-0.8	-1.4	—
+ Share-based Payments	0.7	2.9	2.2	0.7	—
+ Unrealised FX (Gain) / Loss	7.3	0.4	1.6	-8.6	—
+ Other Non-cash Items	1.3	0.4	-0.2	0.6	—
+ Other Reconciling Items	14.4	8.3	0.8	9.3	—
Changes in Working Capital
+ Inventories	-15.5	-27.1	-66.3	14.1	—
+ Trade Receivables — Current	-78.8	-63.8	50.7	-137.4	—
+ Other Financial Assets — Current	21.0	-4.8	1.8	-10.9	—
+ Other Financial Assets — Non-current	-1.4	-5.5	-0.0	-0.5	—
+ Other Current Assets	8.2	-40.4	-33.8	-16.1	—
+ Other Non-current Assets	5.1	-3.7	-0.5	-14.4	—
+ Trade Payables — Current	-8.7	30.1	54.6	105.0	—
+ Other Financial Liabilities — Current	-28.4	28.8	-8.7	29.4	—
+ Other Financial Liabilities — Non-current	7.7	5.1	3.5	47.8	—
+ Other Current Liabilities	12.1	-5.1	8.7	35.1	—
+ Other Non-current Liabilities	-0.1	0.0	0.0	0.0	—
+ Provisions — Current	2.1	-1.2	-3.2	1.7	—
+ Provisions — Non-current	3.6	0.3	-3.9	1.7	—
Cash from Operating Activities
Profit Before Tax (per I/S)	192.8	135.8	-74.4	-106.5	45.6
+ Total Adjustments (incl. Working Capital)	47.7	50.4	186.4	304.9	—
Cash from Operations (pre-tax)	240.5	186.2	112.1	198.4	—
+ Income Taxes Paid	61.7	29.5	17.1	6.2	—
Cash from Operating Activities	178.8	156.7	94.9	192.2	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	207.3	427.3	356.2	147.5	—
+ Disp of Fixed Assets	1.2	1.7	3.8	46.6	—
+ Purchase of Investments (Equity / Debt)	2.4	6.2	0.0	0.0	—
+ Sale of Investments (Equity / Debt)	0.0	0.0	7.9	0.0	—
+ Interest Received — Investing	0.5	4.5	0.8	1.4	—
+ Other Inflows / (Outflows) — Investing	-0.1	-6.4	4.5	-2.1	—
Cash from Investing Activities	-208.2	-433.8	-339.1	-101.6	—
Cash from Financing Activities
+ Proceeds from Other Equity Instruments	0.0	0.8	1.6	1.3	—
+ Proceeds from Borrowings	95.0	251.1	264.3	146.5	—
+ Repayment of Borrowings	22.5	-89.2	-58.6	88.7	—
+ Payment of Lease Liabilities	0.0	0.0	5.2	11.0	—
+ Payment of Finance Lease Liabilities	1.8	3.8	—	—	—
+ Interest Paid	27.2	36.1	63.9	122.7	—
+ Dividends Paid	20.7	20.7	13.9	1.9	—
+ Other Inflows / (Outflows) — Financing	0.0	0.0	0.0	-0.4	—
Cash from Financing Activities	22.8	280.4	241.4	-76.8	—
Net Changes in Cash (pre-FX)	-6.5	3.3	-2.8	13.8	—
Net Changes in Cash	-6.5	3.3	-2.8	13.8	—
Closing Cash	10.9	14.9	—	—	—
Reference Items
EBITDA	286.1	244.3	99.3	141.8	168.7
EBITDA Margin %	17.15	13.44	5.96	7.68	8.84
Free Cash Flow (CFO − Capex)	-28.4	-270.6	-261.2	44.7	44.7
Free Cash Flow to Equity	—	32.4	-3.5	-35.7	—
Free Cash Flow per Basic Share	-3.08	-29.32	-28.30	4.84	4.84
Price to Free Cash Flow	—	—	—	—	44.14
Cash Flow to Net Income	1.26	1.62	-1.22	-1.95	—
Cash Paid for Taxes	61.7	29.5	17.1	6.2	—
Cash Paid for Interest	27.2	36.1	63.9	122.7	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.